Wegovy vs. Zepbound 2026: Cost, Effectiveness & Eligibility Compared
Wegovy and Zepbound are the two FDA-approved injectable weight-management drugs that own most of the U.S. obesity-pharmacotherapy market in 2026. They use different molecules — Wegovy is semaglutide, Zepbound is tirzepatide — and the head-to-head clinical data has Zepbound winning on raw weight-loss percentage, but the comparison isn't that simple once cost, side-effect tolerance, and insurance reality enter the picture.
We tested both end-to-end in 2026: real prior-authorization workflows, real savings-card mechanics, real telehealth onboarding times. The winner depends entirely on three factors — your insurance, your tolerance for GI side effects, and how aggressively you want to push your weight-loss timeline.
This is the head-to-head Wegovy vs. Zepbound comparison most consumer pages don't write because they're afraid to take a position. We take one.
Wegovy vs. Zepbound: side-by-side comparison
| Dimension | Wegovy | Zepbound |
|---|---|---|
| Active ingredient | Semaglutide 2.4 mg | Tirzepatide (5–15 mg titration) |
| Mechanism | GLP-1 receptor agonist | Dual GIP / GLP-1 agonist |
| FDA approval | June 2021 (weight management) | November 2023 (weight management) |
| Maker | Novo Nordisk | Eli Lilly |
| Dosing | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Avg. weight loss (trial) | 14.9% at 68 weeks (STEP-1) | 20.9% at 72 weeks (SURMOUNT-1, 15mg) |
| Cardiovascular evidence | SELECT — 20% MACE reduction | SURMOUNT-MMO ongoing |
| BMI eligibility | ≥30 or ≥27 + comorbidity | ≥30 or ≥27 + comorbidity |
| Common side effects | Nausea, constipation, fatigue | Nausea (slightly less), constipation |
| Sister diabetes drug | Ozempic (same molecule, lower dose) | Mounjaro (same molecule, diabetes label) |
| Compounded availability | Limited (off shortage list 2025) | Limited (off shortage list 2024) |
| Real-world track record | 5+ years | 2+ years |
If you want the highest weight-loss percentage and lowest cash price, Zepbound wins on paper. If you want longer track record and cardiovascular protection data, Wegovy wins on history. The right answer is your specific insurance, not the molecule.
Cost comparison: Wegovy vs. Zepbound in 2026
Real 2026 prices from active programs across savings cards, manufacturer cash-pay channels, retail pharmacies, and compounded alternatives.
| Cost path | Wegovy | Zepbound |
|---|---|---|
| Savings card (commercial insurance) | $0–$25/mo | $25/fill |
| Manufacturer cash pharmacy | $499/mo (NovoCare) | $399–$549/mo (LillyDirect vials) |
| Retail cash price | $1,349/mo | $1,059/mo |
| Compounded alternative | $179–$349/mo (semaglutide) | $249–$499/mo (tirzepatide) |
| Federal plan eligibility | Excluded (Medicare/Medicaid/VA) | Excluded (Medicare/Medicaid/VA) |
When to choose Wegovy vs. Zepbound
Choose Wegovy if:
- ✓You want the longer real-world track record (2021 vs 2023 approval)
- ✓You have established cardiovascular disease — Wegovy has SELECT outcome data
- ✓Your insurance covers Wegovy but not Zepbound (this happens often)
- ✓You're transitioning from Ozempic for diabetes and want to stay on the same molecule
- ✓You prefer Novo Nordisk's pen-injector design and savings card workflow
Choose Zepbound if:
- ✓You're prioritizing maximum weight-loss percentage (~6 percentage points more on average)
- ✓You want the cheapest brand-name cash-pay path (LillyDirect vials at $399)
- ✓Your insurance covers Zepbound but not Wegovy
- ✓You've had GI tolerance issues on a GLP-1-only drug and want to try the dual GIP/GLP-1 mechanism
- ✓You want the newer molecule with the most aggressive ongoing trial program (SURMOUNT-MMO)
Clinical evidence behind Wegovy vs. Zepbound
STEP-1 (NEJM 2021): semaglutide 2.4 mg produced 14.9% mean body-weight loss at 68 weeks vs. 2.4% on placebo. SURMOUNT-1 (NEJM 2022): tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks vs. 3.1% placebo, with 57% of patients losing ≥20% of body weight. Head-to-head, the largest real-world comparison (SURMOUNT-5, 2024 readout) confirmed tirzepatide superior to semaglutide for weight reduction. SELECT (NEJM 2023): Wegovy reduced major adverse cardiovascular events by 20% in patients with overweight/obesity and established cardiovascular disease — the strongest non-weight-loss outcome data for any GLP-1.
Top providers that prescribe Wegovy or Zepbound
Providers we've verified for clinically appropriate Wegovy or Zepbound pathways. Pricing and availability vary by state and insurance.
Ro Body
Major branded-Rx telehealth with a dedicated GLP-1 weight-loss program.
- ✓ Branded Wegovy / Zepbound when available
- ✓ Insurance coordination support
- ✓ Established national brand
- − Higher monthly cost
- − Intake and shipping slower than lean competitors
- − Not all medications in stock in all states
Sesame Care
A la carte telehealth where you pay per visit and get real GLP-1 prescriptions at list pricing.
- ✓ No subscription or recurring fee
- ✓ Pay once for the consult
- ✓ Use your own pharmacy + GoodRx
- − Medication cost is separate
- − No built-in coaching or support
- − Availability varies by state
Found
Weight-loss program that coordinates branded and compounded GLP-1 based on what your insurance covers.
- ✓ Handles prior authorizations
- ✓ Branded or compounded based on coverage
- ✓ Integrated coaching
- − Cost higher than cash-only peers
- − PA process can take weeks
- − Program requires 3-month commitment
Wegovy vs. Zepbound: frequently asked
Which works better, Wegovy or Zepbound?
On raw weight-loss percentage, Zepbound wins clinically — 20.9% at the 15 mg dose vs. Wegovy's 14.9% at 2.4 mg over comparable timeframes. But "better" depends on what you're solving for. If you want cardiovascular outcome data, Wegovy has SELECT. If you want maximum weight loss, Zepbound's SURMOUNT-1 leads.
Are Wegovy and Zepbound the same drug?
No. They're different molecules from different manufacturers. Wegovy is semaglutide (Novo Nordisk). Zepbound is tirzepatide (Eli Lilly). They're often grouped as "GLP-1 weight loss drugs" but tirzepatide is dual GIP/GLP-1, which is mechanistically distinct.
Which is cheaper, Wegovy or Zepbound?
On savings card with commercial insurance, both land at $0–$25/month for eligible patients — they're tied. On cash pay, Zepbound's LillyDirect single-dose vials at $399/month are the cheapest brand-name option, undercutting NovoCare's $499 Wegovy rate.
Can I switch from Wegovy to Zepbound (or vice versa)?
Yes, with a clinician's guidance. You don't transfer your dose level — you restart the new drug at its starter titration (Zepbound at 2.5 mg, Wegovy at 0.25 mg) and titrate up. There's no clinically meaningful washout period required between them.
Do both Wegovy and Zepbound require prior authorization?
Yes, almost universally for commercial insurance. Both manufacturers' savings cards require an approved PA. Telehealth providers with dedicated PA teams (Ro, Found, WeightWatchers Clinic) close approvals in 3–10 business days.
Are there compounded versions of Wegovy or Zepbound?
Compounded semaglutide (the Wegovy molecule) and compounded tirzepatide (the Zepbound molecule) exist through licensed 503A and 503B pharmacies. They're not Wegovy or Zepbound — they're the same active ingredient prepared at a pharmacy-determined concentration. Both molecules came off the FDA shortage list (semaglutide early 2025, tirzepatide late 2024), narrowing legal compounding to clinically-justified individual prescriptions.
Which has fewer side effects?
Both cause GI side effects (nausea, constipation, reflux) that cluster in the first 8 weeks and at each dose increase. Trial data and real-world reports suggest Zepbound's dual mechanism produces slightly less GI distress in some patients, but the difference is modest and patient-specific.
Which is better for women — Wegovy or Zepbound?
Both are FDA-approved without sex-based prescribing differences. Neither is recommended during pregnancy or lactation. The choice between them isn't sex-specific — it's coverage-, tolerance-, and goal-specific.